Halozyme Therapeutics Share Holder Equity 2010-2024 | HALO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Halozyme Therapeutics share holder equity for 2024 was $0.364B, a 334.11% increase from 2023.
Halozyme Therapeutics share holder equity for 2023 was $0.084B, a 50.64% decline from 2022.
Halozyme Therapeutics share holder equity for 2022 was $0.17B, a 13.79% decline from 2021.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Halozyme Therapeutics share holder equity for 2024 was $0.364B, a 334.11% increase from 2023.
Halozyme Therapeutics share holder equity for 2023 was $0.084B, a 50.64% decline from 2022.
Halozyme Therapeutics share holder equity for 2022 was $0.17B, a 13.79% decline from 2021.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231.2B
Amgen (AMGN)	$160B
Gilead Sciences (GILD)	$137.1B
Vertex Pharmaceuticals (VRTX)	$123.3B
Bristol Myers Squibb (BMY)	$113.2B
CSL (CSLLY)	$80.1B
GSK (GSK)	$76.6B
Regeneron Pharmaceuticals (REGN)	$76.1B
Argenex SE (ARGX)	$39.3B
Alnylam Pharmaceuticals (ALNY)	$32.5B
BioNTech SE (BNTX)	$28.3B
BeiGene (ONC)	$23.9B
Biogen (BIIB)	$20.1B
Illumina (ILMN)	$15.4B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.9B
Genmab (GNMSF)	$14.7B
Incyte (INCY)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
BioMarin Pharmaceutical (BMRN)	$13.1B
Moderna (MRNA)	$13B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.4B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.3B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.2B
Repligen (RGEN)	$9.1B
Bio-Rad Laboratories (BIO.B)	$8.7B